I would suggest the high cost per patient would be predominantly driven by hospital and pediatrician costs for conducting the trial. They may also be paying patient expenses for participation. I would think drug cost would only make up a part of the cost.
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
I would suggest the high cost per patient would be predominantly...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.784B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $3.531M | 255.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 502 | $13.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.78 | 2834 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 502 | 13.740 |
1 | 3816 | 13.730 |
4 | 3805 | 13.720 |
2 | 1998 | 13.710 |
1 | 1807 | 13.690 |
Price($) | Vol. | No. |
---|---|---|
13.780 | 2834 | 1 |
13.840 | 3013 | 3 |
13.860 | 315 | 1 |
13.870 | 1807 | 1 |
13.880 | 365 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online